Quantumup
Nov 5, 4:08 PM
Stifel reitd
$AMLX Buy45.
[
$CRNX $RYTM [MBX VOGX]]
Stifel said—We remain Buy rated following AMLX's 3Q26 update as most importantly avexitide's PBH NDA remains on-track to be submitted by YE26
Following the very strong topline data, we think approval is de-risked--and near-term, AMLX will present the LUCIDITY data at Obesity Week (Nov 15th) which we think should confirm what is a favorable clinical profile (we don't expect any surprises)
Big picture for the stock, the focus remains commercial where, as discussed at our recent Cardiometabolic Day (LINK), we think management makes a strong case for a large orphan opportunity which, in our view (even as the Street has broadly become optimistic on the PBH TAM) allows for meaningful upside over time (we model ~
$2B)
And more broadly, the compelling rare end comps continue to build (CRNX, RYTM, etc.)
Elsewhere, the pipeline continues to progress with IND-enabling studies for their long-acting ongoing (IND 2027) and Cohort 4 of LUMINA now enrolling
0 replies